Section 12.52.995. Definitions.

	(a)  In this chapter, unless the context requires otherwise,  
		(1) "ACPE" means Accreditation Council for Pharmacy Education;  
		(2) "approved program" means a continuing education activity that is a live program, home study, or other mediated instruction delivered by an approved or accredited provider;  
		(3) "approved provider" means an individual, institution, organization, association, corporation, or agency offering an approved program under 12 AAC 52.340 and is not an accredited provider;  
		(4) "authorized inspector" means a member of the board or an investigator with the division assigned occupational licensing functions in the department;  
		(5) "blood" means whole blood collected from a single donor and processed either for transfusion or further manufacturing;  
		(6) "blood component" means that part of blood separated by physical or mechanical means;  
		(7) "board" means the Alaska Board of Pharmacy;  
		(8) "care provider" means a person or organization that by the nature of experience and training is qualified, in the opinion of the board, to provide substance abuse counseling, rehabilitation, or related services to the public through established and recognized treatment programs;  
		(9) "consultant pharmacist" means a licensed pharmacist retained by written agreement with an institutional facility to consult on a routine basis with an institutional facility about the practice of pharmacy as it relates to that facility;  
		(10) "contact hour" means a unit of measure of educational credit that is equivalent to approximately 50 minutes of participation in an organized learning experience; a continuing education unit or "CEU" is equivalent to ten contact hours;  
		(11) "DEA" means the United States Drug Enforcement Administration;  
		(12) "department" means the Department of Commerce, Community, and Economic Development;  
		(13) "direct supervision" means supervision that ensures adequate safety controls either by personal supervision or through a telepharmacy system;  
		(14) "home study" and "other mediated instruction" mean continuing education activities that are not conducted as live programs, including audio tapes, video tapes, television, computer assisted instruction, journal articles, or monographs;  
		(15) "institutional facility" means a  
			(A) hospital;  
			(B) long-term care facility, including a nursing home, convalescent home, or other related facility;  
			(C) mental health facility;  
			(D) rehabilitation center;  
			(E) psychiatric center;  
			(F) developmental disability center;  
			(G) drug abuse treatment center;  
			(H) family planning clinic;  
			(I) penal institution;  
			(J) hospice; or  
			(K) public health facility;  
		(16) "institutional pharmacy" means a pharmacy located in an institutional facility;  
		(17) "licensee" means a person who is licensed under AS 08.80  and this chapter;  
		(18) "live program" means an on-site continuing education activity, including a lecture, symposium, live teleconference, or workshop;  
		(19) "sterile pharmaceutical" means a drug dosage form free from living microorganisms (aseptic);  
		(20) "wholesale distribution" means distribution of prescription drugs to a person other than a consumer or patient, but does not include an activity described in 12 AAC 52.695;  
		(21) "central pharmacy" means a pharmacy providing remote pharmacy services through a telepharmacy system;  
		(22) "personal supervision" means supervision that includes visual or physical proximity to ensure adequate safety controls;  
		(23) "pharmacy" includes a central pharmacy and a remote pharmacy;  
		(24) "remote pharmacy" means a facility that provides pharmacy services, including the storage and distribution of prescription drugs, drug regimen review, and patient counseling through a telepharmacy system;  
		(25) "still image capture" means a specific image captured electronically from a video or other image capture device;  
		(26) "store and forward" means a video or still image record that is saved electronically for future review;  
		(27) "telepharmacy system" means a system under the direct supervision of a licensed pharmacist that monitors the dispensing and distribution of prescription drugs and provides for related drug use review and patient counseling services through a computer link and a video link with sound;  
		(28) "accredited provider" means an individual, institution, organization, association, corporation, or agency that is recognized by the ACPE as able to provide quality continuing education programs;  
		(29) "filling pharmacist" means a pharmacist participating in shared pharmacy services that processes or fills a prescription order for a patient;  
		(30) "filling pharmacy" means a pharmacy participating in shared pharmacy services that processes or fills a prescription order for a patient;  
		(31) "requesting pharmacist" means a pharmacist participating in shared pharmacy services that forwards a prescription order to another participating pharmacy or pharmacist to be processed or filled;  
		(32) "requesting pharmacy" means a pharmacy participating in shared pharmacy services that forwards a prescription order to another participating pharmacy to be processed or filled;  
		(33) "shared pharmacy services" means a system allowing the processing by a participating pharmacist or a pharmacy of a request from another participating pharmacist or pharmacy to process or fill a prescription drug order, including dispensing, drug utilization review, claims adjudication, refill authorizations, therapeutic interventions, and institutional order review;  
		(34) "dispenser" means a practitioner who delivers a controlled substance to an ultimate user or research subject under the lawful order of a practitioner; in this paragraph, "delivers" includes the prescribing and administering of a controlled substance and the packaging, labeling. or compounding necessary to prepare the substance for delivery;  
		(35) "profile" means a compilation of data concerning a patient, a dispenser, a practitioner, or a controlled substance.  
	(b)  In AS 08.80.315(3), "other persons or governmental agencies" include investigators for the department who are assigned to conduct investigations under AS 08.  
	(c)  In AS 08.80.030(b)(7), "monitoring of drug therapy" means a review of the drug therapy regimen of patients by a pharmacist for the purpose of evaluating and rendering advice to the prescribing practitioner regarding adjustment of the regimen. "Monitoring of drug therapy" includes  
		(1) collecting and reviewing records of patient drug use histories;  
		(2) measuring and reviewing routine patient vital signs, including pulse, temperature, blood pressure, and respiration; and  
		(3) ordering and evaluating the results of laboratory tests relating to drug therapy, including blood chemistries and cell counts, drug levels in blood, urine, tissue, or other body fluids, and culture and sensitivity tests that are performed in accordance with a written protocol approved under 12 AAC 52.240.  

Authorities

08.80.005;08.80.030;08.80.157;44.62.125

Notes

Reference

7 AAC 120.114

Authority

AS 08.80.005 AS 08.80.030 AS 08.80.157 Editor's note: As of Register 171 (October 2004), the regulations attorney made technical revisions under AS 44.62.125(b)(6) to reflect the name change of the Department of Community and Economic Development to the Department of Commerce, Community, and Economic Development made by ch. 47, SLA 2004 and the corresponding title change of the commissioner of community and economic development. With Register 180, January 2007 and under the authority of AS 44.62.125, the regulations attorney changed obsolete terminology concerning the division of occupational licensing and the division of banking and securities in conformity with ch. 14, SLA 2005 and to reflect the transfer of certain corporations functions within the Department of Commerce, Community, and Economic Development. ________________________

History

Eff. 1/16/98, Register 145; am 5/5/2000, Register 154; am 11/10/2001, Register 160; am 8/21/2002, Register 163; am 2/15/2006, Register 177; am 8/12/2007, Register 183; am 9/11/2010, Register 195; am 12/29/2011, Register 200; am 8/1/2014, Register 211